Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 13/20 | 0.37 |
| ▸ | RAF1 | P04049 | 8/20 | 0.35 |
| ▸ | CTRC | Q99895 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14424566 | 0.85 | GSK3B (0.36) | PDE3BPDE3ABRAFCTRCRET | |
| SCHEMBL17808729 | 0.79 | MB (0.39) | BRAFRAF1CTRCDDR2 | |
| SCHEMBL10267990 | 0.77 | PDE3B (0.40) | PDE3BPDE3ABRAFRAF1CRBN | |
| SCHEMBL11986935 | 0.77 | NNMT (0.37) | — | |
| SCHEMBL10308677 | 0.76 | ENPP1 (0.45) | CTRCCRBN | |
| SCHEMBL10308521 | 0.76 | MB (0.39) | BRAFRAF1CTRCEGFR | |
| SCHEMBL783097 | 0.75 | UHRF1 (0.41) | — | |
| SCHEMBL797188 | 0.75 | HTR2A (0.38) | PDE3BPDE3ABRAFRAF1EGFR | |
| SCHEMBL26878390 | 0.74 | PDE3B (0.40) | PDE3BPDE3ABRAFRAF1EGFR | |
| SCHEMBL3009275 | 0.74 | DAO (0.37) | PDE3BPDE3ABRAFRAF1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-9670231-B2 | Fused tricyclic amide compounds as multiple kinase inhibitors | BEIGENE, LTD. (KY) | 2017-06-06 | — | — | US | disclosed |
| US-9670231-B2 | Fused tricyclic amide compounds as multiple kinase inhibitors | BEIGENE, LTD. (KY) | 2017-06-06 | — | — | US | disclosed |
| US-20160159820-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2016-06-09 | — | — | US | disclosed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
| US-8088794-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7858623-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858623-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | PDE3B 4413/4885PDE3A 4447/4885BRAF 761/4885 |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | HGF, HGFAC, MET | PDE3B 1652/4885PDE3A 1554/4885BRAF 212/4885 |
| US-20160159820-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BRAF, EGFR, ERBB2 | PDE3B 3874/4885PDE3A 3923/4885BRAF 1/4885 |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | HGF, HGFAC, MET | PDE3B 1500/4885PDE3A 1526/4885BRAF 228/4885 |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | PDE3B 1652/4885PDE3A 1554/4885BRAF 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.